10128-91-3

Usage

Uses

Used in Chemical Synthesis:
Methyl 2-oxo-1,2-dihydro-3-pyridinecarboxylate is used as a key intermediate in the synthesis of various complex chemical compounds. Its versatile structure allows it to be a valuable building block in the creation of a wide range of molecules, making it an essential component in chemical research and development.
Used in Pharmaceutical Industry:
Methyl 2-oxo-1,2-dihydro-3-pyridinecarboxylate is used as a starting material in the production of certain pharmaceutical compounds. Its unique properties enable it to be a crucial component in the development of new drugs, contributing to advancements in medicine and healthcare.
Used in Research Laboratories:
Methyl 2-oxo-1,2-dihydro-3-pyridinecarboxylate is used as a research chemical in academic and industrial research settings. Its presence in the synthesis of various compounds makes it a valuable tool for scientists and researchers working on the development of new materials and technologies.
Used in Industrial Applications:
Methyl 2-oxo-1,2-dihydro-3-pyridinecarboxylate is used in various industrial processes, particularly in the production of specialty chemicals and materials. Its role in the synthesis of complex compounds makes it an important ingredient in the manufacturing of a wide range of products.
It is important to handle and store Methyl 2-oxo-1,2-dihydro-3-pyridinecarboxylate with care due to its potential health hazards, ensuring safety in both research and industrial settings.

InChI:InChI=1/C7H7NO3/c1-11-7(10)5-3-2-4-8-6(5)9/h2-4H,1H3,(H,8,9)

Upstream product

• 67-56-1 methanol 
• 609-71-2 2-hydroxy-3-carboxypyridine 
• 609-71-2 1,2-dihydro-2-oxonicotinic acid 
• 149-73-5 trimethyl orthoformate 
• 17758-13-3 1-phenyl-2(1H)-pyrimidinone 
• 108-59-8 malonic acid dimethyl ester 
• 17758-14-4 1-p-tolylpyrimidin-2(1H)-one 
• 28369-76-8 2-hydroxynicotinic acid chloride 
• 393-55-5 2-fluoronicotinic acid 

Downstream Products

• 252921-14-5 methyl 2-(3-nitrophenyl)-3-pyridinecarboxylate 
• 252921-34-9 2-(3-aminophenyl)-3-pyridinecarboxylic acid methyl ester 
• 868171-80-6 methyl 1-(phenyl)-2-oxo-1,2-dihydropyridine-3-carboxylate 
• 1428155-21-8 C₂₈H₂₃F₂N₇O₃ 
• 1428155-22-9 N-(3-fluoro-4-(9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-ylamino)phenyl)-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide 
• 1428155-24-1 N-(3-fluoro-4-(9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-ylamino)phenyl)-2-oxo-1-(4-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamide 
• 1428155-25-2 N-(3-fluoro-4-(9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6-ylamino)phenyl)-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamide 
• 1428155-27-4 C₂₃H₁₄F₂N₆O₃ 
• 1428155-28-5 C₂₃H₁₄F₂N₆O₃ 
• 1428155-29-6 C₂₄H₁₄F₄N₆O₃ 
• 1428155-33-2 C₂₃H₁₆FN₇O₂ 
• 1428155-34-3 C₂₄H₁₆F₃N₇O₂ 
• 1428155-40-1 C₂₃H₁₅F₂N₇O₂ 
• 1428155-41-2 C₂₃H₁₅F₂N₇O₂ 

Relevant academic research and scientific papers

Highly regiocontrolled and stereocontrolled syntheses of polysubstituted aminocyclohexanes: mild inverse-electron-demand Diels–Alder cycloadditions of electrophilic 2-pyridones

Strongly electrophilic N-arenesulfonyl-2-pyridone-3-carboxylate methyl esters complex with zinc dibromide and then react with nucleophilic benzyl vinyl ether or benzyloxyallene to achieve inverse-electron-demand Diels–Alder (IEDDA) cycloadditions. These cycloadducts are produced on gram scale and in 77–89% yields, importantly without the use of high pressure. These 4+2 cycloadditions strongly favor regioselective and stereoselective formation of endo bicyclic lactams as established by X-ray crystallography. These bicyclic lactams undergo useful reactions, including reductive cleavage of the N-sulfonyl group, exo-syn-dihydroxylations, and lactam ring-opening to produce a variety of aminocyclitols.

POLYCYCLIC AMIDES AS UBE2K MODULATORS FOR TREATING CANCER

Provided are compounds of Formula (I) and pharmaceutically acceptable salts and compositions thereof, which are useful for treating conditions associated with modulation of UBE2K.

THROMBIN INHIBITORS, FORMULATIONS, AND USES THEREOF

Thrombin-inhibiting acylated pyrazole-pyridone compounds of formula (II) are disclosed herein, as well as pharmaceutical compositions, including tablets, that contain acylated pyrazole- pyridone compounds. These compounds are useful for the treatment and prevention of thrombin-related related diseases and disorders. Processes for making tablets containing acylated pyrazole-pyridones are also included.

MODIFIED COMPOUND OF ANDROGRAPHOLIDE

The present disclosure discloses a modified compound of andrographolide, and particularly discloses a compound shown in formula (I) and (II) or a pharmaceutically acceptable salt thereof.

Development of a Practical Synthesis of a Peripherally Selective Noradrenaline Reuptake Inhibitor Possessing a Chiral 6,7-trans-Disubstituted-1,4-oxazepane as a Scaffold

A practical synthesis of a peripherally selective noradrenaline reuptake inhibitor that has a chiral 6,7-trans-disubstituted-1,4-oxazepane as a new class of scaffold is described. The amino alcohol possessing the desired stereochemistry was obtained with excellent dr and ee, starting from a commercially available aldehyde via a Morita-Baylis-Hillman reaction, Michael addition, isolation as maleic acid salt, reduction, and diastereomeric salt formation with (+)-10-camphorsulfonic acid. The desired single stereoisomer obtained at an early stage of the synthesis was used for seven-membered ring formation in fully telescoped processes, providing the chiral 6,7-trans-disubstituted-1,4-oxazepane efficiently. In addition to controls of dr and ee of the chiral 1,4-oxazepane, and control of N,O-selectivity in SN2 reaction of the intermediate mesylate with a pyridone derivative, finding appropriate intermediates that were amenable to isolation and upgrade of purity enabled a practical chiral HPLC separation-free, column chromatograph-free synthesis of the drug candidate with excellent chemical and optical purities in a higher overall yield.

Indole-based small molecular C-MET inhibitor

The invention belongs to the technical field of medicines, and provides indole compounds for treating lung cancer, breast cancer, kidney cancer, pancreatic cancer, colorectal cancer, stomach cancer and other cancers.

COMPOUND HAVING ZNF143 INHIBITORY ACTIVITY AND USE THEREOF

PROBLEM TO BE SOLVED: To provide a compound having a ZNF143 inhibitory activity as well as to provide a ZNF143 inhibitory agent and pharmaceutical composition containing the same. SOLUTION: Provided is a compound represented by formula (I) or a salt thereof as well as a ZNF143 inhibitory agent containing the same and a pharmaceutical composition having the same as an active ingredient. A-B-C-D (I)[A is H, a methyl group, a naphthyl group, a phenyl group or a nitrogen-containing heterocyclic ring; B is as shown below, and C is an amide bond or a heteroaromatic ring containing N and O; D is a substituted/unsubstituted phenyl group or a monocyclic heteroaromatic ring containing N or S; and C and D are both fused heterocyclic ring or the like optionally having a substituent group.]. SELECTED DRAWING: Figure 1 COPYRIGHT: (C)2016,JPOandINPIT

PYRAZOLYL-SUBSTITUTED PYRIDONE COMPOUNDS AS SERINE PROTEASE INHIBITORS

There are provided inter alia pyrazolyl-substituted pyridone compounds, which exhibit biological activity, e.g., inhibitory action, against serine proteases, including thrombin and various kallikreins. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing certain diseases or disorders, which disease or disorder is amenable to treatment or prevention by the inhibition of serine proteases, including thrombin and various kallikreins.

MULTISUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS

There are provided inter alia multisubstituted aromatic compounds useful for the inhibition of kallikrein, which compounds include substituted pyrazolyl or substituted triazolyl. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing certain diseases or disorders, which disease or disorder is amenable to treatment or prevention by the inhibition of kallikrein.

Inhibitors of the TAM subfamily of tyrosine kinases: Synthesis and biological evaluation

The TAM subfamily of Receptor Tyrosine Kinases (RTKs) contains three human proteins of therapeutical interest, Axl, Mer, and Tyro3. Our goal was to design a type II inhibitor specific for this family, i.e. able to interact with the allosteric pocket and with the hinge region of the kinase. We report the synthesis of several series of purine analogues of BMS-777607. The structural diversity of the designed inhibitors was expected to modify the interactions formed in the binding site and consequently to modulate their selectivity profiles. The most potent inhibitor 6g exhibits Kds of 39, 42, 65 and 200 nM against Axl, Mer, Met and Tyro3 respectively. Analysis of the affinity of 6g for active and inactive forms of Abl1, an RTK protein that does not belong to the TAM subfamily, together with the binding modes of 6g predicted by docking studies, indicates that 6g displays some selectivity for the TAM family and may act as a type II inhibitor. Crown Copyright